Hospital
Concordia Parish Hospital Service District Number One
Concordia Parish Hospital Service District Number One was paid $9.16M by Medicaid between Jan 2018 and Dec 2024, across 92 billing codes. Its largest line is 99284, emergency room visit (serious) — 29% of everything it billed.
33Billing provider infoCONCORDIA PARISH HOSPITAL SERVICE DISTRICT NUMBER ONE
FERRIDAY, LA 71334
FERRIDAY, LA 71334
33aNPI1144227935assigned 07/07/2005
33bProvider typeCritical Access Hospital
28Total paid$9.16M
24GClaims263,979
24DCodes billed92
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Louisiana
Rank by total paid#6 of 40
Median peer was paid$3.19M
This provider vs. median2.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 21,242 | $598K | |
| 2019 | 28,361 | $685K | |
| 2020 | 20,906 | $520K | |
| 2021 | 36,946 | $1.43M | |
| 2022 | 53,241 | $1.91M | |
| 2023 | 58,114 | $2.62M | |
| 2024incomplete | 45,169 | $1.40M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 29% | 15,907 | 13,311 | $2.61M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 18% | 14,747 | 12,767 | $1.69M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 15% | 6,495 | 5,165 | $1.41M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 11% | 3,118 | 2,319 | $1.03M |
| 70450 | Computed tomography, head or brain; without contrast material | 5.9% | 2,831 | 2,015 | $539K |
| 71045 | Radiologic examination, chest; single view | 3.2% | 9,576 | 6,609 | $295K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.2% | 8,882 | 6,824 | $205K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.8% | 5,355 | 4,470 | $161K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 1.8% | 2,448 | 2,083 | $161K |
| 80053 | Comprehensive metabolic panel | 1.7% | 26,960 | 20,654 | $152K |
| 85027 | 1.1% | 28,633 | 22,037 | $102K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 2,153 | 1,781 | $52K |
80 more codes
| 87428 | <1% | 2,929 | $47K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,234 | $45K |
| 36415 | Collection of venous blood by venipuncture | <1% | 28,764 | $45K |
| 83880 | <1% | 3,299 | $40K | |
| 82553 | <1% | 8,452 | $37K | |
| 80305 | <1% | 4,522 | $34K | |
| 84512 | <1% | 8,812 | $32K | |
| 80061 | Lipid panel | <1% | 2,912 | $28K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 339 | $27K |
| 71250 | <1% | 136 | $26K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,077 | $25K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,383 | $25K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 361 | $25K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 2,004 | $24K |
| 82550 | <1% | 8,658 | $21K | |
| G0378 | Hospital observation service, per hour | <1% | 20 | $21K |
| 81025 | <1% | 2,873 | $18K | |
| 81001 | <1% | 11,712 | $17K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,363 | $15K |
| 87430 | <1% | 1,188 | $12K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 687 | $12K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 1,268 | $11K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 2,013 | $11K |
| 87276 | <1% | 1,004 | $10K | |
| 83605 | <1% | 2,179 | $10K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 535 | $10K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 47 | $9K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,526 | $9K |
| 87275 | <1% | 1,003 | $9K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,157 | $9K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 194 | $8K |
| 83690 | <1% | 2,001 | $7K | |
| 83735 | <1% | 2,509 | $6K | |
| 84439 | <1% | 895 | $6K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 14 | $6K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 479 | $5K |
| 85379 | <1% | 905 | $4K | |
| 85730 | <1% | 1,757 | $4K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,279 | $3K |
| 82150 | <1% | 868 | $3K | |
| 85610 | <1% | 2,098 | $3K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 93 | $3K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 178 | $3K |
| 87040 | <1% | 714 | $3K | |
| 81003 | <1% | 1,930 | $2K | |
| 82607 | <1% | 246 | $2K | |
| 87420 | <1% | 216 | $2K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 773 | $2K |
| 85007 | <1% | 1,235 | $2K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 378 | $2K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 17 | $1K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 239 | $1K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 285 | $1K |
| J3490 | Unclassified drugs | <1% | 764 | $1K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 658 | $1K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 132 | $974.82 |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 2,434 | $771.27 |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 25 | $723.52 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 535 | $611.10 |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 121 | $581.71 |
| 82962 | <1% | 396 | $576.79 | |
| 87186 | <1% | 113 | $464.38 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 157 | $461.18 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 185 | $372.03 |
| 82043 | <1% | 102 | $312.12 | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 77 | $269.59 |
| J2704 | Injection, propofol, 10 mg | <1% | 774 | $218.14 |
| 83550 | <1% | 40 | $202.96 | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 48 | $178.42 |
| 83540 | <1% | 40 | $150.25 | |
| 82728 | <1% | 15 | $149.93 | |
| 73562 | <1% | 16 | $125.86 | |
| 87077 | <1% | 31 | $121.20 | |
| 73630 | <1% | 13 | $92.52 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 37 | $73.72 |
| 84100 | <1% | 18 | $56.88 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 15 | $34.43 |
| 85652 | <1% | 17 | $24.90 | |
| A9270 | Non-covered item or service | 0% | 295 | $0.00 |
| 90853 | Group psychotherapy (other than of a multiple-family group) | 0% | 1,056 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSMITH, NEKEISHA (ADMINISTRATOR)
| Provider | Location | Paid |
|---|---|---|
| Concordia Parish Hospital Service District Number One | Ferriday, LA | $3.15M |
| Concordia Parish Hospital Service District Number One | Vidalia, LA | $1.23M |
| Concordia Parish Hospital Service District Number One | Ferriday, LA | $354K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.